Menu Search
Equities

Atara Biotherapeutics Inc

AT20:DEU

Atara Biotherapeutics Inc

Actions
  • Price (EUR)7.00
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+36.59%
  • Beta--
Data delayed at least 15 minutes, as of Jun 28 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.

  • Revenue in USD (TTM)62.39m
  • Net income in USD-181.05m
  • Incorporated2012
  • Employees165.00
  • Location
    Atara Biotherapeutics Inc2380 Conejo Spectrum St, Suite 200THOUSAND OAKS 91320United StatesUSA
  • Phone+1 (805) 623-4244
  • Fax+1 (302) 636-5454
  • Websitehttps://www.atarabio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.